• For Patients: Clinical Trials
  • Publications
  • Careers
  • Contact Us
INOVIO Pharmaceuticals
  • About INOVIO
    • Purpose, Mission and Values
    • Leadership
    • Partnerships
  • DNA Medicines Technology
    • Optimized Plasmid Design and Delivery
    • DNA Medicines Explained
    • The Promise of DNA Medicine
    • NEXT GEN DNA MEDICINE
  • DNA Medicines Pipeline
  • Investors & Media
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Shareholder Services
    • FAQ
  • For Patients: Clinical Trials
  • Publications
  • Careers
  • Contact Us
INOVIO Pharmaceuticals
NEWS ALERT

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

  • About INOVIO
    • Purpose, Mission and Values
    • Leadership
    • Partnerships
  • DNA Medicines Technology
    • Optimized Plasmid Design and Delivery
    • DNA Medicines Explained
    • The Promise of DNA Medicine
    • NEXT GEN DNA MEDICINE
  • DNA Medicines Pipeline
  • Investors & Media
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Shareholder Services
    • FAQ
  • For Patients: Clinical Trials
  • Publications
  • Careers
  • Contact Us

Press Releases

INOVIO to Report Second Quarter 2023 Financial Results on August 9, 2023

Posted on July 26, 2023

INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Posted on June 23, 2023

INOVIO to Present at the 2023 Jefferies Healthcare Conference

Posted on May 25, 2023

INOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

Posted on May 23, 2023

INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights

Posted on May 10, 2023

New Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023

Posted on May 8, 2023

INOVIO to Present at the 2023 RBC Capital Markets Global Healthcare Conference

Posted on May 5, 2023

INOVIO to Report First Quarter 2023 Financial Results on May 10, 2023

Posted on April 28, 2023

INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023

Posted on April 27, 2023

European Committee for Orphan Medicinal Products Provides Positive Opinion on INOVIO’s Application for Orphan Drug Designation for INO-3107

Posted on April 26, 2023
Page 8 of 17« First«...678910...»Last »

SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases

INOVIO Pharmaceuticals
  • About Inovio
  • DNA Medicines Technology
  • DNA Medicines Pipeline
  • Investors & Media
  • For Patients
  • Publications
  • Careers
  • Contact Us
  • Safe Harbor Statement
  • Expanded Access
  • Privacy Policy
  • Terms & Conditions

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.